Condition category
Cancer
Date applied
18/03/2016
Date assigned
21/03/2016
Last edited
13/07/2016
Prospective/Retrospective
Prospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Samuel Smith

ORCID ID

http://orcid.org/0000-0003-1983-4470

Contact details

Centre for Cancer Prevention
Queen Mary University of London
Wolfson Institute of Preventive Medicine
Charterhouse Square
London
EC1M 6BQ
United Kingdom
020 7882 5698
sam.smith@qmul.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

v1.0

Study information

Scientific title

Access to chemoprevention in the NHS

Acronym

Study hypothesis

H1. GPs will be more willing to prescribe tamoxifen if they are told the patient is at high risk of breast cancer compared with moderate risk of breast cancer
H2. GPs will be more willing to prescribe tamoxifen if they are told the family history clinician has written the first prescription, compared with GPs told they are requested to write the first prescription
H3. GPs will be more willing to prescribe tamoxifen if they are told the family history clinician has written the first prescription, and this effect will be greatest among those in the high risk compared with moderate risk scenario

Ethics approval

Queen Mary Ethics of Research Committee, 22/02/2016, ref: QMREC1481

Study design

Randomised 2 x 2 factorial design of a patient vignette

Primary study design

Interventional

Secondary study design

Randomised factorial design

Trial setting

Other

Trial type

Other

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet

Condition

Prescribing behaviour

Intervention

GPs will be randomised to read one of four vignettes describing a 45 year old patient at increased risk of breast cancer. The GPs are told to imagine the patient has consulted them and they have been referred to a family history clinic in secondary care. Two vignettes will describe the patient as having a high risk of breast cancer (≥30% lifetime risk), and two of the vignettes will describe her as having a moderate risk of breast cancer (17-30% lifetime risk). The vignette describes the hypothetical discussion that took place in secondary care, and suggests the patient is interested in taking tamoxifen for primary prevention purposes. Two of the vignettes request that the GP writes the first prescription for tamoxifen and continues to act as the main prescriber. The remaining two vignettes describe a situation in which the secondary care clinician has written the first prescription, and the GP is being asked to take over as the main prescriber.

The GPs will be allocated randomly to one of the four scenarios:
1. Moderate risk patient and GP is the first prescriber
2. High risk patient and GP is the first prescriber
3. Moderate risk patient and GP is the second prescriber
4. High risk patient and GP is the second prescriber

Intervention type

Behavioural

Phase

Drug names

Primary outcome measures

The main effects of:
1. Risk level
2. First prescriber
on willingness to prescribe tamoxifen. This will be measured immediately after reading the vignette using the item: 'Would you be willing to write the prescription for [patient name]?', 'Not at all willing', 'probably not willing' 'probably willing' 'definitely willing'.

Secondary outcome measures

All outcomes will be measured immediately after the GP has read the vignette.
1. Interaction between risk level and first prescriber on willingness to prescribe tamoxifen
2. Willingness to prescribe within pre-defined respondent groups:
2.1. Males vs. female GPs
2.2. GP specialist trainees vs. GP partners vs. Salaried GPs
2.3. Special interest in cancer/preventive medicine/family history/genetics vs. none of these
2.4. Deprived (quintiles 1-3) vs. non-deprived (quintiles 4-5) practices based on IMD score
3. Wanting to speak with a colleague before writing the prescription ('Would you want to speak with anyone else before you decided whether to write this prescription?' 'yes' 'no')
4. Comfort in discussing the possible benefits and harms of tamoxifen ('How comfortable would you feel discussing the possible benefits and harms of tamoxifen with [patient name]?' 'very uncomfortable' 'quite uncomfortable' 'quite comfortable' 'very comfortable'
5. Comfort in managing the care of the patient ('If [patient name] started taking tamoxifen, how comfortable would you feel managing her care for the duration of the prescription?' 'very uncomfortable' 'quite uncomfortable' 'quite comfortable' 'very comfortable')
6. Factors considered during the decision-making process:
('How much do you agree or disagree that the following factors affected your decision of whether or not to write a prescription for [patient name]?' 'Strongly disagree' 'disagree' 'agree' 'strongly agree'
6.1. Evidence for the benefits of the drug
6.2. The evidence for the harms of the drug
6.3. Prescribing ‘off-label’
6.4. The first prescription being made by a family history clinician
6.5. The first prescription being made by the GP
6.6.The financial costs of tamoxifen
6.7. Patient risk level
6.8. Patient’s interest in taking tamoxifen
6.9. Patient’s awareness of the possible harms and benefits
6.10. GP’s confidence in knowledge of tamoxifen
6.11. Patient’s support from the genetics clinician
6.12. The attitudes of the GP’s colleagues who are at the same career stage
6.13. The attitudes of the GP’s colleagues who are more senior
6.14. The prescribing budget in the General Practice
6.15. The policy of the local Clinical Commissioning Group
6.16. The existence of NICE guidelines (or national equivalent)
6.17. Other
7. Free text comments at end of the survey

Overall trial start date

18/02/2016

Overall trial end date

30/09/2016

Reason abandoned

Eligibility

Participant inclusion criteria

1. General practitioner (or GP specialist trainee)
2. Based in the UK

Participant type

Health professional

Age group

Adult

Gender

Both

Target number of participants

1000

Participant exclusion criteria

Not a General Practitioner

Recruitment start date

28/03/2016

Recruitment end date

29/04/2016

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Queen Mary University of London
Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Charterhouse Square
London
EC1M 6BQ
United Kingdom

Sponsor information

Organisation

Queen Mary University of London

Sponsor details

Mile End Road
London
E1 4NS
United Kingdom

Sponsor type

University/education

Website

Funders

Funder type

Charity

Funder name

Cancer Research UK

Alternative name(s)

CRUK

Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Publish main results in a 'white paper' on behalf of Cancer Research UK and in a scientific manuscript. The primary and secondary outcomes will be published in both publications.

Intention to publish date

Participant level data

Stored in repository

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

13/07/2016: Internal review.